Affiliation:
1. Peggy and Charles Stephenson Cancer Center; University of Oklahoma Health Sciences Center; Oklahoma City OK USA
2. Department of Pathology; University of Oklahoma Health Sciences Center; Oklahoma City OK USA
3. Department of Biochemistry and Molecular Biology; University of Oklahoma Health Sciences Center; Oklahoma City OK USA
4. Department of Pharmacology; Boehringer Ingelheim RCV GmbH & Co KG; Vienna Austria
Funder
National Cancer Institute
National Institute of General Medical Sciences
Presbyterian Health Foundation
Boehringer Ingelheim International GmbH
Presbyterian Health Foundation Team Science Grant
National Institutes of Health
Reference41 articles.
1. The Concise Guide To PHARMACOLOGY 2017/18: Catalytic receptors;Alexander;Br J Pharmacol,2017
2. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Cancer Discov,2014
3. Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers;Curtis;Br J Pharmacol,2018
4. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial;Drilon;Lancet Oncol,2016
5. Cabozantinib in progressive medullary thyroid cancer;Elisei;J Clin Oncol,2013
Cited by
62 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献